Out of Our Minds

In the 1940s there were early and exciting indications that drugs like LSD, psilocybin and MDMA might be a resource for those suffering from PTSD, obsessive-compulsive disorder (OCD), anxiety, depression, and addiction. The possibility of finding keys to unlock and treat complex mental health disorders seemed near, but it took decades before work resumed on the study of the psychology, neuroscience, biochemistry and impact of these drugs. Now, we’re poised on a cultural and scientific precipice as we rethink the possibilities and risks of mental health treatment with psychedelic drugs.

We’re assembling a team of neuroscientists, biochemists, clinicians and behavioral scientists to help you understand what we know today about the potential risks—and benefits—of hallucinogenic drugs

Calling all contributors!

Scientists – contribute your knowledge!

We're looking for active researchers to be contributors to this report. Think you're a good fit? When you join the Massive Science Consortium you'll get to apply to contribute to this report.

Consortium Membership

Only a one-time, $10 enrollment fee

Confirm Eligibility

We expect all scientists joining the Consortium to have:

A graduate's degree in a STEM field or enrollment in a STEM Master's program